Phase 3 Head and Neck Cancer Trial, Recruiting NCT06248996 Sponsor: Lund University Hospital Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 3 Head and Neck Cancer Trial, Recruiting

NCT06248996
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are at least 18 years old.
  • People who have been diagnosed (confirmed by tissue or cell testing) with a specific type of head and neck cancer — in the throat (oropharynx), lower throat (hypopharynx), voice box (larynx), or mouth — that has not been treated before and has not spread to distant parts of the body, and where the planned treatment is radiation therapy (with or without chemotherapy) aimed at curing the cancer.
  • People whose tumour meets a minimum size requirement: for a type called p16-positive oropharyngeal cancer, the tumour must be estimated at 30 cc or larger; for all other locations or p16-negative oropharyngeal cancer, the tumour must be estimated at 20 cc or larger (confirm with trial site on how this is measured).
  • People whose treatment plan may include surgery after radiation — such as a salvage procedure or removal of lymph nodes in the neck — but not surgery before radiation; a small diagnostic procedure such as removal of a lymph node or tonsil for testing purposes does not prevent participation.
  • People who are reasonably fit and able to carry out daily activities, as measured by a standard medical scale (WHO/ECOG performance status 0–2) (confirm with trial site).
  • People who are able to understand the information about the trial and are willing to provide written consent to participate.

Who may not be able to join:

  • People who have previously had radiation treatment to the head or neck area.
  • People who have had, or currently have, another cancer — with some exceptions: straightforward skin cancers of a specific type (basal cell carcinoma, or early-stage squamous cell skin cancer with at least one year of follow-up), or any other cancer where the person has been cancer-free for at least three years.
  • People who have two or more separate head and neck cancers diagnosed at the same time.
  • People whose cancer is located in the nasopharynx (the upper part of the throat behind the nose).
  • People whose cancer is located in the sinuses or nasal cavity.
  • People who have another serious illness that is expected to significantly shorten life expectancy (less than three years).
  • People who are pregnant or breastfeeding.
  • People with certain psychiatric conditions, addiction disorders, or other medical conditions that, in the opinion of the trial doctor, may affect their ability to follow the trial requirements.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Maria Gebre-Medhin, MD, Lund University Hospital

Phone: +46 46 17 75 20

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Lund University Hospital
Registry
ClinicalTrials.gov
Start date
4 March 2024
Est. completion
4 March 2028

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

Local tumour control after treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov